Key Points
- Longitude Capital Partners II sold 7,739 shares on Jan. 23 at $4.06 (≈$31,420) and additionally sold 46,000 on Jan. 30 at $4.54 and 27,500 on Feb. 2 at $4.25, totaling 81,239 shares sold (≈$357,135) while retaining 4,029,245 shares valued at about $16.36M.
- Rapid Micro Biosystems reported quarterly EPS of ($0.26) in line with estimates and revenue of $7.84M (slightly above expectations), but remains unprofitable with negative ROE and analysts projecting -1.1 EPS for the year; consensus rating is "Moderate Buy" with an average price target of $8.00.
- The stock opened at $4.35 (up ~3.8% that session) with a market cap around $192.8M and a 12‑month trading range of $1.86 to $4.94, with the 50‑ and 200‑day moving averages at $3.69 and $3.39 respectively.
Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Get Free Report) major shareholder Longitude Capital Partners Ii, sold 7,739 shares of the stock in a transaction dated Friday, January 23rd. The stock was sold at an average price of $4.06, for a total transaction of $31,420.34. Following the sale, the insider owned 4,029,245 shares of the company's stock, valued at $16,358,734.70. This trade represents a 0.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Longitude Capital Partners Ii, also recently made the following trade(s):
- On Monday, February 2nd, Longitude Capital Partners Ii, sold 27,500 shares of Rapid Micro Biosystems stock. The shares were sold at an average price of $4.25, for a total value of $116,875.00.
- On Friday, January 30th, Longitude Capital Partners Ii, sold 46,000 shares of Rapid Micro Biosystems stock. The stock was sold at an average price of $4.54, for a total value of $208,840.00.
Rapid Micro Biosystems Trading Up 3.8%
Shares of RPID stock opened at $4.35 on Wednesday. The company has a market capitalization of $192.79 million, a P/E ratio of -4.31 and a beta of 1.38. The company has a current ratio of 4.23, a quick ratio of 2.95 and a debt-to-equity ratio of 0.42. The business's 50 day moving average is $3.69 and its two-hundred day moving average is $3.39. Rapid Micro Biosystems, Inc. has a twelve month low of $1.86 and a twelve month high of $4.94.
Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) last released its quarterly earnings results on Friday, November 7th. The company reported ($0.26) EPS for the quarter, hitting the consensus estimate of ($0.26). Rapid Micro Biosystems had a negative return on equity of 73.90% and a negative net margin of 145.11%.The business had revenue of $7.84 million during the quarter, compared to analysts' expectations of $7.60 million. Equities analysts forecast that Rapid Micro Biosystems, Inc. will post -1.1 EPS for the current year.
Institutional Investors Weigh In On Rapid Micro Biosystems
A number of large investors have recently added to or reduced their stakes in RPID. Geode Capital Management LLC raised its position in Rapid Micro Biosystems by 1.6% during the second quarter. Geode Capital Management LLC now owns 204,079 shares of the company's stock worth $704,000 after acquiring an additional 3,143 shares during the last quarter. American Century Companies Inc. grew its position in shares of Rapid Micro Biosystems by 46.1% in the second quarter. American Century Companies Inc. now owns 16,922 shares of the company's stock valued at $58,000 after purchasing an additional 5,341 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Rapid Micro Biosystems during the 2nd quarter worth approximately $144,000. Vanguard Group Inc. raised its position in shares of Rapid Micro Biosystems by 6.7% during the 3rd quarter. Vanguard Group Inc. now owns 965,018 shares of the company's stock worth $3,223,000 after purchasing an additional 60,655 shares during the last quarter. Finally, Evernest Financial Advisors LLC lifted its stake in Rapid Micro Biosystems by 355.1% in the 3rd quarter. Evernest Financial Advisors LLC now owns 200,234 shares of the company's stock valued at $669,000 after buying an additional 156,234 shares in the last quarter. 52.60% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on RPID shares. Wall Street Zen downgraded Rapid Micro Biosystems from a "hold" rating to a "sell" rating in a report on Saturday, January 17th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Rapid Micro Biosystems in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $8.00.
View Our Latest Report on RPID
Rapid Micro Biosystems Company Profile
(
Get Free Report)
Rapid Micro Biosystems (NASDAQ: RPID) develops and commercializes automated microbial detection and contamination control solutions for the life sciences industry. Its flagship offering, the Growth Direct® System, leverages digital imaging and proprietary growth indicator plates to identify and count microorganisms more rapidly than traditional culture-based methods. The company's technology platform is designed to streamline quality control workflows in pharmaceutical, biotechnology and vaccine manufacturing settings, helping clients reduce release times and improve operational efficiency.
In addition to the Growth Direct® System, Rapid Micro Biosystems offers an integrated suite of software and consumables that support automated data capture, analysis and reporting.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
